Composition and uses thereof
AssigneeProgen PG500 Series Pty Ltd
InventorKeith Dredge
Life of this patent
Estimating the term…
Abstract
The present invention relates, inter alia, to methods for the prevention or treatment of cancer, and to compositions, combinations and kits for the treatment or prevention of cancer. In one embodiment, the invention provides a method of treating or preventing cancer, comprising administering to a patient in need thereof an immune checkpoint modulator together with a compound of Formula (I): wherein X is SO3M or H, wherein M is any pharmaceutically acceptable cation; and wherein at least 70% of the X groups is SO3M.
Claims19
A method of treating or preventing cancer, comprising administering to a patient in need thereof an immune checkpoint inhibitor together with a compound of Formula (I):
- wherein X is SO3M or H, wherein M is any pharmaceutically acceptable cation;
- wherein at least 70% of the X groups is SO3M;
- and
- wherein the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor.
A method of treating or preventing cancer, comprising administering to a patient in need thereof Nivolumab together with a compound of Formula (I):
- wherein X is SO3M or H, wherein M is any pharmaceutically acceptable cation;
- and
- wherein at least 70% of the X groups is SO3M.
A pharmaceutical composition or combination comprising a compound of Formula (I) and an immune checkpoint inhibitor, wherein the compound of Formula (I) is:
- wherein X is SO3M or H, wherein M is any pharmaceutically acceptable cation;
- wherein at least 70% of the X groups is SO3M;
- and
- wherein the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor.
A pharmaceutical composition or combination, comprising a compound of Formula (I) and Nivolumab, wherein the compound of Formula (I) is:
- wherein X is SO3M or H, wherein M is any pharmaceutically acceptable cation;
- and
- wherein at least 70% of the X groups is SO3M.
A kit comprising a compound of Formula (I) and an immune checkpoint inhibitor, wherein the compound of Formula (I) is:
- wherein X is SO3M or H, wherein M is any pharmaceutically acceptable cation;
- wherein at least 70% of the X groups is SO3M;
- and
- wherein the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor.
A kit, comprising a compound of Formula (I) and Nivolumab, wherein the compound of Formula (I) is:
- wherein X is SO3M or H, wherein M is any pharmaceutically acceptable cation;
- and
- wherein at least 70% of the X groups is SO3M.
Dependencies are inferred from the claim text.